Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Significance: Synthetic nanoparticles containing either protein or peptide antigen and the immunosuppressant rapamycin are capable of inducing durable and specific resistance to mounting immune responses toward the antigen. This immunological tolerance operates on lymphocytes even after multiple immunogenic challenges with the antigen and adding enhancers of immune responses (adjuvants). As a result, the animals treated with these tolerogenic nanoparticles (tNPs) show reduced allergic hypersensitivity disorders, protection from disease relapse in a model of multiple sclerosis, and prevention of inhibitory antidrug antibody responses in an animal model of hemophilia A. These results show the potential for nanocarriers to modify the immunoreactivity of a given molecule by providing tolerogenic instructions to the immune system, thereby preventing or reversing pathological and neutralizing immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, tolerogenic rapamycin nanoparticles, but not rapamycin in free form, have been shown to be able to inhibit both cellular and humoral immune response and induce Tregs in mice (40).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [40]
Citations
Cites
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106 · cited 7×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“In fact, free rapamycin, administered at an equivalent dose as that used in tNP treatment, showed the opposite trend with respect to inhibition of OVA-specific T-cell expansion and induction of antigen-specific Tregs, perhaps due to the direct effect of free rapamycin on enhancing effector memory T-cell formation (40).”
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (1988) · Nature · doi:10.1038/334676a0 · Cited by 1,565 · cited 1×
“The transgenic BCR is specific for hen egg lysozyme (HEL), and the presence of this protein results in cell activation of MD4 B cells in vivo and in vitro (33).”
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 2×
“However, conventional therapy with free rapamycin requires chronic systemic administration, resulting in broad immunosuppression due to its direct effect on lymphocytes (28), whereas low doses of rapamycin may paradoxically augment effector T-cell memory (29).”
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594 · cited 8×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541 · cited 1×
“The codelivery of antigen and rapamycin provide an instruction set that could allow for the conditioning of tolerogenic DCs capable of inducing CD4+ Treg (22, 23).”
Self-citationUpdated assessment of the prevalence, spectrum and case definition of autoimmune disease
Hayter, S. M., & Cook, M. C. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.02.001 · Cited by 464 · cited 1×
“Clin Rev Allergy Immunol 37(2):114–124.”
Cited by
Items 101–200 of 452
Role of lymph node stroma and microenvironment in T cell tolerance
Saxena, V., Li, L., Paluskievicz, C., Kasinath, V., Bean, A., Abdi, R., Jewell, C. M., & Bromberg, J. S. (2019) · Immunological Reviews · doi:10.1111/imr.12799 · Cited by 79
Galea, R. C., Nel, H. J., Talekar, M., Liu, X., Ooi, J. D., Huynh, M., Hadjigol, S., Robson, K. J., Ting, Y. T., Cole, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126025 · Cited by 72
Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases
Serra, P., & Santamaría, P. (2018) · European Journal of Immunology · doi:10.1002/eji.201747059 · Cited by 68
Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells
Zhang, A.-H., Yoon, J., Kim, Y. C., & Scott, D. W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701800 · Cited by 63
“Experimental FVIII tolerance induction has also been achieved through coadministration of FVIII with rapamycin (28, 29) or with IL-2/IL-2 mAb complexes (30).”
MethodSelf-citationZhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Self-citationGross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 66
Siegler, E. L., Kim, Y. J., & Wang, P. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.08.002 · Cited by 63
“CM, improves drug penetration core Preclinical [23]”
InfluentialPeptide Immunotherapy for Type 1 Diabetes—Clinical Advances
Smith, E., & Peakman, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00392 · Cited by 68
Promises and limitations of immune cell-based therapies in neurological disorders
Hu, X., Leak, R. K., Thomson, A. W., Yu, F., Xia, Y., Wechsler, L. R., & Chen, J. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0028-5 · Cited by 67
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
Kishimoto, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00969 · Cited by 63
“In vitro, in a static tissue culture well, ImmTOR is not more effective than free rapamycin in inducing Tregs (unpublished observation); therefore, we hypothesize that the difference in vivo is related to the selective biodistribution of ImmTOR to lymphoid organs and its preferential uptake by antigen-presenting cells…”
BackgroundInfluentialSelf-citationSands, E., Kivitz, A., DeHaan, W., Leung, S. S., Johnston, L., & Kishimoto, T. K. (2022) · Nature Communications · doi:10.1038/s41467-021-27945-7 · Cited by 61
Self-citationNguyen, T. L., Choi, Y., Im, J., Shin, H., Phan, N. M., Kim, M. K., Choi, S. W., & Kim, J. (2022) · Nature Communications · doi:10.1038/s41467-022-35263-9 · Cited by 63
Sterling, S., Kireta, S., McInnes, S. J. P., Kette, F. D., Sivanathan, K. N., Kim, J., Cueto-Diaz, E. J., Cunin, F., Durand, J., Drogemuller, C., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01625 · Cited by 61
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Casey, L. M., Hughes, K. R., Saunders, M. N., Miller, S. D., Pearson, R. M., & Shea, L. D. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121457 · Cited by 61
Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines
Mitarotonda, R., Giorgi, E. D., Eufrásio-da-Silva, T., Dolatshahi‐Pirouz, A., Mishra, Y. K., Khademhosseini, A., Desimone, M. F., Marzi, M. C. D., & Orive, G. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212726 · Cited by 65
Wang, X., Su, J., Sherman, A., Rogers, G. L., Liao, G., Hoffman, B. E., Leong, K. W., Terhorst, C., Daniell, H., & Herzog, R. W. (2015) · Blood · doi:10.1182/blood-2014-08-597070 · Cited by 58
Engineering self-assembled materials to study and direct immune function
Tostanoski, L. H., & Jewell, C. M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.005 · Cited by 62
“An intriguing recent idea is to employ biomaterials to co-deliver selfantigen with regulatory immune cues to promote the expansion of cells that are self-antigen-specific, but exert tolerogenic or regulatory functions [111, [135] [136] [137] [138] instead of inflammatory attacks.”
Saito, E., Gurczynski, S. J., Kramer, K. R., Wilke, C. A., Miller, S. D., Moore, B. B., & Shea, L. D. (2020) · Science Advances · doi:10.1126/sciadv.abc9317 · Cited by 61
Balmert, S. C., Donahue, C., Vu, J. R., Erdös, G., Falo, L. D., & Little, S. R. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.006 · Cited by 62
CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis
Safari, F., Farajnia, S., Aria, M., Zarredar, H., & Nasrolahi, A. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1437625 · Cited by 61
Li, C., Chen, X., Luo, X., Wang, H., Zhu, Y., Du, G., Chen, W., Chen, Z., Hao, X., Zhang, Z., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.0c05110 · Cited by 59
Hess, K. L., Andorko, J. I., Tostanoski, L. H., & Jewell, C. M. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.052 · Cited by 56
Protein–Polymer Delivery: Chemistry from the Cold Chain to the Clinic
Welch, R. P., Lee, H., Luzuriaga, M. A., Brohlin, O. R., & Gassensmith, J. J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00483 · Cited by 62
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Further, tolerogenic rapamycin nanoparticles, but not rapamycin in free form, have been shown to be able to inhibit both cellular and humoral immune response and induce Tregs in mice (40).”
BackgroundNanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases
Benne, N., ter Braake, D., Stoppelenburg, A. J., & Broere, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864403 · Cited by 57
Regulatory T cell-based therapies for autoimmunity.
Arellano, B., Graber, D. J., & Sentman, C. L. (2016) · PubMed · Cited by 57
Nanoparticles for immune system targeting
Du, J., Zhang, Y. S., Hobson, D., & Hydbring, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.013 · Cited by 57
Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Self-citationTowards programming immune tolerance through geometric manipulation of phosphatidylserine
Roberts, R. A., Eitas, T. K., Byrne, J. D., Johnson, B. M., Short, P., McKinnon, K. P., Reisdorf, S., Luft, J. C., DeSimone, J. M., & Ting, J. P. ‐. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.040 · Cited by 58
“Regardless, the potential therapeutic use of biomaterials to program tolerance in the setting of autoimmunity and transplantation could fundamentally improve the clinical outcomes for millions of patients [25,61].”
BackgroundPlant cell-made protein antigens for induction of Oral tolerance
Daniell, H., Kulis, M. D., & Herzog, R. W. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.06.012 · Cited by 57
“Preclinical data have shown that one can, for example, prevent inhibitor formation in hemophilia mice by co-administration of rapamycin and FVIII or FIX antigen (Maldonado et al., 2015; Moghimi et al., 2011; Nayak et al., 2009).”
BackgroundJohnson, L., Duschl, A., & Himly, M. (2020) · Vaccines · doi:10.3390/vaccines8020237 · Cited by 60
“reported the potential of a tolerogenic nanocarrier system (encapsulated with protein/peptide antigen) to prevent and neutralize a pathological immune response [95].”
BackgroundGene Therapy for Methylmalonic Acidemia: Past, Present, and Future
Chandler, R. J., & Venditti, C. P. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.113 · Cited by 59
“Selecta Biosciences has developed tolerogenic nanoparticles encapsulating rapamycin (ImmTOR or SVP-Rapamycin), which if coadministered with AAV-based vectors provide a dosedependent suppression of humoral and T cell responses against the rAAV capsid enabling rAAV redosing.(46,47) Preliminary testing of Anc80 in combin…”
BackgroundFeng, R., Yu, F., Xu, J., & Hu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120469 · Cited by 55
Li, H., Yang, Y., & Sun, T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.889291 · Cited by 64
“Codelivery of rapamycin, a natural macrolide compound that acts as an allosteric inhibitor of the mammalian target of rapamycin (mTOR) pathway, has been shown to have tolerogenic properties in vitro and in vivo (Maldonado et al., 2015; Tostanoski et al., 2016; Zhang et al., 2016).”
BackgroundCombinatorial drug delivery approaches for immunomodulation
Stewart, J. M., & Keselowsky, B. G. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.013 · Cited by 53
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
Rockenstein, E. M., Ostroff, G. R., Dikengil, F., Rus, F., Mante, M., Florio, J. B., Adame, A., Trinh, I., Kim, C., Overk, C., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1170-17.2017 · Cited by 54
“It has been reported recently that the codelivery of an antigen plus RAP in nanoparticles induced Tregs (Maldonado et al., 2015).”
BackgroundMethodInfluentialBiomaterials-Mediated Engineering of the Immune System
Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 55
Nanomedicine for T‐Cell Mediated Immunotherapy
Li, F., Ouyang, J., Chen, Z., Zhou, Z., Essola, J. M., Ali, B., Wu, X., Zhu, M., Guo, W., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202301770 · Cited by 55
Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies
Virkud, Y. V., Wang, J., & Shreffler, W. G. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8694-z · Cited by 51
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 53
“This tolerance mechanism has been reported in previous studies investigating tolerogenic vaccine concepts [169,170].”
ResultTolerizing Strategies for the Treatment of Autoimmune Diseases: From ex vivo to in vivo Strategies
Cauwels, A., & Tavernier, J. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00674 · Cited by 53
Sadiq, S., Khan, I., Shen, Z., Wang, M., Xu, T., Khan, S. A., Zhou, X., Bahadur, A., Rafiq, M., Sohail, S., et al. (2023) · Molecules · doi:10.3390/molecules28227674 · Cited by 49
“On this basis, Mal-donado et al. [74] proposed synthetic polymeric NPs and rapamycin, which can induce immune tolerance against Streptomyces hygroscopicus, potentially treating allergies, autoimmune diseases, and preventing antidrug antibodies in animal husbandry.”
BackgroundMazor, R., King, E. M., Onda, M., Cuburu, N., Addissie, S., Crown, D., Liu, X.-F., Kishimoto, T. K., & Pastan, I. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717063115 · Cited by 49
“Unlike general immune suppressive therapies, SVP-R has a strong affinity to accumulate in the lymph nodes and spleen (21), where it is selectively endocytosed by antigen-presenting cells (Fig.”
BackgroundSelf-citationPei, W., Wan, X., Shahzad, K. A., Zhang, L., Song, S., Jin, X., Wang, L., Zhao, C., & Shen, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s164500 · Cited by 48
“17,18 For 19–23 For example, the gold NPs carrying aryl hydrocarbon receptor ligand and myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide have been demonstrated to induce tolerogenic DCs that promote the differentiation of regulatory T cells (Tregs) in vitro and in mice EAE model and, thus,…”
Controlled delivery of a metabolic modulator promotes regulatory T cells and restrains autoimmunity
Gammon, J. M., Tostanoski, L. H., Adapa, A. R., Chiu, Y.-C., & Jewell, C. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.277 · Cited by 53
“Someof the important drugs that have been tested in this area include mycophenolic acid (MPA) [26], rapamycin [27,28], and 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) [29].”
BackgroundLei, H., Reinke, P., Volk, H., Lv, Y., & Wu, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02667 · Cited by 49
Brzezicka, K., Arlian, B. M., Wang, S., Olmer, M., Lotz, M., & Paulson, J. C. (2022) · ACS Nano · doi:10.1021/acsnano.2c05643 · Cited by 48
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development
Salazar‐Fontana, L. I., Desai, D. D., Khan, T. A., Pillutla, R. C., Prior, S., Ramakrishnan, R., Schneider, J., & Joseph, A. M. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0030-z · Cited by 48
Controlled release strategies for modulating immune responses to promote tissue regeneration
Dumont, C. M., Park, J., & Shea, L. D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.014 · Cited by 48
Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury
Dumont, C. M., Margul, D. J., & Shea, L. D. (2016) · Cells Tissues Organs · doi:10.1159/000446646 · Cited by 49
“…and polystyrene nanoparticles containing antigen peptides has been shown to induce antigen-specific tolerance for the prevention and treatment of experimental autoimmune encephalomyelitis (EAE) – the murine multiple sclerosis model [Getts et al., 2012; Hunter et al., 2014; Maldonado et al., 2015].”
BackgroundManipulating human dendritic cell phenotype and function with targeted porous silicon nanoparticles
Stead, S. O., McInnes, S. J. P., Kireta, S., Rose, P. D., Jesudason, S., Rojas‐Canales, D. M., Warther, D., Cunin, F., Durand, J., Drogemuller, C., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.017 · Cited by 48
“These realisations have led to an emerging research focus on the use of nanoparticles to target immune cells, including DC, for tolerogenicity in autoimmunity and cancer immunotherapy [12-16].”
BackgroundCafferata, E. A., Álvarez, C., Diaz, K. T., Maureira, M., Monasterio, G., González, F. E., Covarrubias, C., & Vernal, R. (2018) · Oral Diseases · doi:10.1111/odi.13023 · Cited by 48
Luo, Y., Liang, L., Gan, Y.-J., Liu, J., Zhang, Y., Fan, Y.-N., Zhao, G., Czarna, A., Lu, Z.-D., Du, X., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c10885 · Cited by 46
Ruiz‐de‐Angulo, A., Bilbao‐Asensio, M., Cronin, J., Evans, S. J., Clift, M. J. D., Llop, J., Feiner, I. V. J., Beadman, R., Zamacola, K., & Rivas, J. C. M. (2020) · iScience · doi:10.1016/j.isci.2020.101499 · Cited by 46
Antigen-specific immunotherapies for autoimmune disease
Buckner, J. H. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01201-w · Cited by 54
“Similar approaches can also promote adaptive T reg cells 77 .”
Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery
Yun, Y., An, J., Kim, H. J., Choi, H. K., & Cho, H. (2025) · Nanoscale · doi:10.1039/d4nr04778h · Cited by 49
Pang, L., Macauley, M. S., Arlian, B. M., Nycholat, C. M., & Paulson, J. C. (2017) · ChemBioChem · doi:10.1002/cbic.201600702 · Cited by 48
Smith, E. S., Porterfield, J. E., & Kannan, R. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.009 · Cited by 46
“And even with several immune challenges, no induction of EAE was seen in these mice [120].”
BackgroundVaccines for immune tolerance against autoimmune disease
Kim, A., Xie, F., Abed, O. A., & Moon, J. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115140 · Cited by 48
“…and colleagues developed tolerogenic NPs (tNPs) composed of PLGA, pegylated poly-lactic acid (PLA-PEG), rapamycin, and protein or peptide antigens that modify adaptive immune responses and produce a lasting tolerance able to protect against multiple immunogenic challenges with antigen [57].”
BackgroundJarai, B. M., Kolewe, E. L., Stillman, Z. S., Raman, N., & Fromen, C. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816662-8.00018-7 · Cited by 50
Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells
Enterina, J. R., Jung, J., & Macauley, M. S. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.07.010 · Cited by 46
“[102] Maldonado RA, LaMothe RA, Ferrari JD, Zhang A-H, Rossi RJ, Kolte PN, et al.”
BackgroundKwiatkowski, A. J., Stewart, J. M., Cho, J. J., Avram, D., & Keselowsky, B. G. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000164 · Cited by 44
Tackling Autoimmunity with Nanomedicines
Feng, X., Liu, J., Xu, W., Gao, L., & Ding, J. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0102 · Cited by 44
Horwitz, D. A., Bickerton, S., & Cava, A. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681062 · Cited by 47
“More recently this group has used nanoliposomes carrying an AHR ligand to treat EAE (64).”
BackgroundInfluentialAdvances in dendritic cell targeting nano-delivery systems for induction of immune tolerance
Lin, G., Wang, J., Yang, Y., Zhang, Y., & Sun, T. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1242126 · Cited by 46
Immunostimulation and Immunosuppression: Nanotechnology on the Brink
Fontana, F., Figueiredo, P., Bauleth‐Ramos, T., Correia, A., & Santos, H. A. (2018) · Small Methods · doi:10.1002/smtd.201700347 · Cited by 47
Chen, N., Kroger, C. J., Tisch, R., Bachelder, E. M., & Ainslie, K. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800341 · Cited by 43
Engineering Biomaterials to Direct Innate Immunity
Oakes, R. S., Froimchuk, E., & Jewell, C. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800157 · Cited by 45
Recent advances of nanotechnology application in autoimmune diseases – A bibliometric analysis
He, R., Li, L., Zhang, T., Ding, X., Xing, Y. T., Zhu, S., Gu, Z., & Hu, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101694 · Cited by 45
Tolerogenic Nanovaccine for Prevention and Treatment of Autoimmune Encephalomyelitis
Park, J.-W., Le, Q., Wu, Y., Lee, J., & Oh, Y. (2022) · Advanced Materials · doi:10.1002/adma.202202670 · Cited by 42
Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis
Kammona, O., & Kiparissides, C. A. (2020) · Brain Sciences · doi:10.3390/brainsci10060333 · Cited by 41
Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling
Barroso, A., Mahler, J. V., Fonseca-Castro, P. H., & Quintana, F. J. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.003 · Cited by 42
Ilyinskii, P. O., Michaud, A. M., Rizzo, G. L., Roy, C. J., Leung, S. S., Elkins, S. L., Capela, T., Chowdhury, A., Li, L., Chandler, R. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.015 · Cited by 39
“ImmTOR particles encapsulating rapamycin were designed to mitigate the formation of anti-drug antibodies against co-administered biologic drugs through the induction of tolerogenic dendritic cells and antigen-specific regulatory T cells (Tregs).(41,42) This approach has been validated with multiple biologic therapies…”
BackgroundSelf-citationClinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
In vivo induction of regulatory T cells for immune tolerance in hemophilia
Wang, X., Terhorst, C., & Herzog, R. W. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.10.001 · Cited by 39
Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases
Richardson, N., Ng, S. T. H., & Wraith, D. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01586 · Cited by 40
Yin, N., Wang, Y., Cao, Y., Huang, Y., Jin, L., Zhang, S., Liu, J., Zhang, T., Lv, Z., Liu, Y., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101619 · Cited by 39
Overcoming Immune Dysregulation with Immunoengineered Nanobiomaterials
Scott, E. A., Karabin, N. B., & Augsornworawat, P. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044603 · Cited by 39
Kishimoto, T., Fournier, M., Michaud, A. M., Rizzo, G. L., Roy, C. J., Capela, T., Nukolova, N. V., Li, N., Doyle, L., Fu, F.-N., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103125 · Cited by 215
Self-citationGammon, J. M., Carey, S. T., Saxena, V., Eppler, H. B., Tsai, S. J., Paluskievicz, C., Xiong, Y., Li, L., Ackun‐Farmmer, M. A., Tostanoski, L. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36225-5 · Cited by 39
Ascoli, V., Lo‐Coco, F., Torelli, G., Vallisa, D., Cavanna, L., Bergonzi, C., & Luppi, M. (2002) · PubMed · Cited by 43
Rhodes, K. R., Tzeng, S. Y., Iglesias, M., Lee, D., Storm, K., Neshat, S. Y., VanDyke, D., Lowmaster, S. M., Spangler, J. B., Raimondi, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.add8693 · Cited by 37
“Toward the goal of establishing antigen-specific immune tolerance, polymeric particles have been used to deliver antigen, alone (24–26) or in combination with immunosuppressants or other tolerogenic cues (27, 28), to mitigate the risk of exacerbating the autoreactive immune response (29).”
BackgroundLiu, M., Feng, D., Liang, X., Li, M., Yang, J., Wang, H., Pang, L., Zhou, Z., Yang, Z., Kong, D., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00525 · Cited by 36
Nuzzo, D., & Picone, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168866 · Cited by 36
“PLGA nanoparticles loaded with PLP139–151 peptide and rapamycin, an immunosuppressive compound, through an intravenous and/or subcutaneous administration led to complete inhibition of disease relapses [59].”
BackgroundImpact of Siglecs on autoimmune diseases
Brzezicka, K., & Paulson, J. C. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101140 · Cited by 40
Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway
Dreismann, A. K., Hallam, T. M., Tam, L. C. S., Nguyen, C. V., Hughes, J. P., Ellis, S., & Harris, C. L. (2022) · Immunological Reviews · doi:10.1111/imr.13149 · Cited by 37
Engineering antigen-specific immunological tolerance
Kontos, S., Grimm, A. J., & Hubbell, J. A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.05.005 · Cited by 36
The Role of Regulatory T Cells in the Regulation of Upper Airway Inflammation
Palmer, C., Mulligan, J. K., Smith, S. E., & Atkinson, C. (2017) · American Journal of Rhinology and Allergy · doi:10.2500/ajra.2017.31.4472 · Cited by 40
Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research
Al-Lawati, H., Aliabadi, H. M., Makhmalzadeh, B. S., & Lavasanifar, A. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1420053 · Cited by 38
Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future
Derdelinckx, J., Cras, P. P., Berneman, Z. N., & Cools, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624685 · Cited by 36
“A final approach is to use nanoparticles to co-administer autoantigens together with tolerogenic pharmacological agents, which has been used in the context of EAE in combination with rapamycine (105, 106) and dexamethasone (107).”
BackgroundPolymer nanotherapeutics to correct autoimmunity
Su, T., Feng, X., Yang, J.-Z., Xu, W., Liu, T., Zhang, M., Ding, J., & Chen, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.036 · Cited by 34
Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment
Souri, M., Chiani, M., Farhangi, A. A., Mehrabi, M. R., Nourouzian, D., Raahemifar, K., & Soltani, M. (2022) · Nanomaterials · doi:10.3390/nano12050783 · Cited by 37
“VANs including gold nanoparticles are also used to codeliver immunoregulatory drugs or self-antigens as adjuvants for block autoimmune response [160,161].”
BackgroundBiomaterial Strategies for Selective Immune Tolerance: Advances and Gaps
Carey, S. T., Bridgeman, C. J., & Jewell, C. M. (2023) · Advanced Science · doi:10.1002/advs.202205105 · Cited by 37
The Use of Adjuvants for Enhancing Allergen Immunotherapy Efficacy
Chesné, J., Schmidt‐Weber, C. B., & Bieren, J. E. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.08.009 · Cited by 33
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
“Transient co-administration of FVIII and rapamycin-nanoparticles similarly induced lasting tolerance in the hemophilia A mouse model and also diminished preexisting inhibitors (46, 47).”
BackgroundPotential for Targeting Myeloid Cells in Controlling CNS Inflammation
Ifergan, I., & Miller, S. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571897 · Cited by 35
“using PLGA nanoparticles loaded PLP139−151 together with rapamycin, an inhibitor of the mTOR pathway, and demonstrating that a single dose of these particles injected at the peak of disease were able to protect from relapses (243).”
MethodChen, X., Du, G., Bai, S., Dijia, L., Li, C., Hou, Y., Zhang, Y., Zhang, Z., Gong, T., Fu, Y. S., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101307 · Cited by 34
Melittin‐Carrying Nanoparticle Suppress T Cell‐Driven Immunity in a Murine Allergic Dermatitis Model
Liu, Z., Fan, Z., Liu, J., Wang, J., Xu, M., Li, X., Xu, Y., Lu, Y., Han, C., & Zhang, Z. (2023) · Advanced Science · doi:10.1002/advs.202204184 · Cited by 33
Regulatory dendritic cells: profiling, targeting, and therapeutic application
Thomson, A. W., & Ezzelarab, M. B. (2018) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000565 · Cited by 32
Metadata
- Authors
- Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., Johnston, L., Farokhzad, O. C., Langer, R., Scott, D. W., von Andrian, U. H., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Uniformed Services University of the Health Sciences (US)
- Brigham and Women's Hospital (US)
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
- Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115-6017; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-12-29
- Volume
- 112
- Issue
- 2
- Pages
- E156-65
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4299193
- OpenAlex
- W2092747941
- Cited by
- 441
- References
- 48
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 31 · 2023: 36 · 2022: 45 · 2021: 42 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 50 · 2016: 24 · 2015: 23
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Juvenile Diabetes Research Foundation International (15-2011-265)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- polymeric nanoparticles, rapamycin, biodegradable nanoparticles, TLR agonists, regulatory T cells, B cell tolerance, T cell activation inhibition, experimental autoimmune encephalomyelitis, hemophilia A, factor VIII, hypersensitivity, autoimmune disease, allergy, antidrug antibodies, immunomodulation
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antigens, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Factor VIII, Female, Hemocyanins, Hemophilia A, Humans, Hypersensitivity, Delayed, Immune Tolerance, Immunosuppression Therapy, Immunosuppressive Agents, Mice, Inbred BALB C, Oligodeoxyribonucleotides, Ovalbumin, Peptide Fragments, Peptides, Polyglycolic Acid, Proteins, Recombinant Proteins, CD4-Positive T-Lymphocytes, Lactic Acid, Sirolimus, Mice, Nanoparticles, Nanocapsules, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.